Integrated care for asthma
Christopher Riley, Morton Warner, Carolyn Semple Piggot, Amanda Pullen, John Wyn Owen in Releasing Resources to Achieve Health Gain, 2018
In addition to the Hospital Anxiety and Depression Scale12, two further measures of psychosocial outcome were applied. The first was derived from the Asthma Self Efficacy Scale13. This was intended to assess the degree to which patients considered themselves able to control their asthma successfully while experiencing a number of well-recognized behavioural, emotional or environmental ‘trigger factors’. The second measure consisted of an adaptation of the Living with Asthma Scale14, originally considered to reflect the degree to which patients have adapted their life-styles to accommodate the demands or limitations caused by the presence of asthma. In the version of the scale used here, attention was focused on the interactions between asthma and ‘social and physical function’.
Mindfulness in Neurological Conditions
Giles N. Yeates, Fiona Ashworth in Psychological Therapies in Acquired Brain Injury, 2019
This lady in her early 60s with secondary progressive multiple sclerosis (MS), MS-related pain, fatigue and disability and marital difficulties was also suffering with symptoms of anxiety and possibly low mood, which were thought by her referring neurologist to be exacerbating the severity of her MS symptoms. Of particular interest, she reported that her pain was made worse by stress, by which it seemed that she meant both anxiety and angry feelings. On a questionnaire measure (Hospital Anxiety and Depression Scale, Zigmond, & Snaith, 1983) she scored at a high level for symptoms of anxiety and not depression, although I thought her mood was at least sub-optimal (Anxiety, 14/21; Depression, 0/21; clinical cut-offs at 11).
Development of palliative medicine in the United Kingdom and Ireland
Eduardo Bruera, Irene Higginson, Charles F von Gunten, Tatsuya Morita in Textbook of Palliative Medicine and Supportive Care, 2015
35 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370. 36 Mitchell AJ, Meader N, Symonds P. Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: A meta-analysis. JAffect Disord 2010;126:335-348.37 Holland JC, Bultz BD. The NCCN guideline for distress management: A case for making distress the sixth vital sign. J Natl Compr Canc Netw 2007;5:3-7.
Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women
Published in Climacteric, 2018
L. Gao, T. Zheng, W. Xue, Y. Wang, Y. Deng, H. Zuo, A. Sun
The symptoms of menopause were assessed through a modified Kupperman Menopausal Index (mKMI). It included 13 symptoms (hot flushes/sweating, paresthesia, insomnia, nervousness, melancholia, vertigo, fatigue, arthralgia and myalgia, headaches, palpitations, formication, urinary infection and sexual complaints). A scale ranging from 0 to 3 points is used to describe the severity of the complaints. The highest score is 63. The Menopause-Specific Quality of Life (MENQOL) questionnaire was used to evaluate patients’ quality of life8. The Chinese version consisted of 27 items which were divided into four categories of vasomotor (three items), psychosocial (seven items), physical (14 items) and sexual (three items) sections9. The severity of each symptom was assessed on a seven-point scale. In this questionnaire, higher scores are associated with lower quality of life10. The Hospital Anxiety and Depression Scale was used to evaluate anxiety and depression in the participants. The higher scores indicate the more obvious state of anxiety or depression.
Pilot evaluation of a coping-oriented supportive program for people with spinal cord injury during inpatient rehabilitation
Published in Disability and Rehabilitation, 2019
Yan Li, Daniel Bressington, Wai-Tong Chien
Hospital Anxiety and Depression Scale. Participants’ mood status was assessed by the 14-item Hospital Anxiety and Depression Scale, including levels of anxiety (seven items) and depression (seven items). Participants were asked to rate each item on a four-point scale, from 0 – “not at all” to 3 – “very often indeed”; higher subtotal scores indicated higher levels of anxiety and depression. This scale has been widely used in people with physical disability and has very satisfactory internal consistency (Cronbach’s alpha = 0.93 for Hospital Anxiety and Depression Scale – Anxiety and 0.90 for Hospital Anxiety and Depression Scale – Depression) and good content validity [44]. The Chinese version of Hospital Anxiety and Depression Scale [45] indicated high equivalence with the original English version (concordance rates 87–97%), and satisfactory Cronbach’s alphas for anxiety and depression subscales (0.81 and 0.74, respectively). The cutoff points of 9 for both morbid/clinical depression and anxiety of Chinese people with SCI were used, as suggested by Leung et al. [45] and Zheng et al. [46].
Using Virtual Reality to investigate multitasking ability in individuals with frontal lobe lesions
Published in Neuropsychological Rehabilitation, 2019
Tanya Denmark, Jessica Fish, Ashok Jansari, Jignesh Tailor, Keyoumars Ashkan, Robin Morris
Measures of apathy, anxiety and depression were also used, since such difficulties are common in people with tumours involving the frontal lobe. For apathy, the Apathy Evaluation Scale (AES) was used, an 18-item scale developed by Marin, Biedrzycki, and Firinciogullari (1991) specifically for use in populations with brain-related pathology. The AES evaluates the overt behavioural, cognitive, and emotional aspects of goal-directed behaviour (Marin et al., 1991). Each AES form yielded a total score, with higher scores indicating the presence of a greater degree of apathy. Cut-off scores of 41 were used as stated in the AES guidelines. The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) was used as a screening measure of anxiety and depression, with the two subscales each scoring in the ranges of 0–21: scores of 0–7 are considered normal, 8–10 borderline, and above 11 clinically significant.